KYNTRA BIO INC (KYNB) Stock Fundamental Analysis

NASDAQ:KYNB • US31572Q8814

7.05 USD
+0.12 (+1.73%)
Last: Mar 2, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall KYNB gets a fundamental rating of 2 out of 10. We evaluated KYNB against 520 industry peers in the Biotechnology industry. KYNB has a bad profitability rating. Also its financial health evaluation is rather negative. KYNB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • KYNB had positive earnings in the past year.
  • KYNB had a negative operating cash flow in the past year.
  • KYNB had negative earnings in each of the past 5 years.
  • KYNB had negative operating cash flow in 4 of the past 5 years.
KYNB Yearly Net Income VS EBIT VS OCF VS FCFKYNB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 157.40%, KYNB belongs to the top of the industry, outperforming 99.81% of the companies in the same industry.
Industry RankSector Rank
ROA 157.4%
ROE N/A
ROIC N/A
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KYNB Yearly ROA, ROE, ROICKYNB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

  • The Profit Margin of KYNB (2598.87%) is better than 99.62% of its industry peers.
  • With an excellent Gross Margin value of 345.69%, KYNB belongs to the best of the industry, outperforming 99.62% of the companies in the same industry.
  • KYNB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 2598.87%
GM 345.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
KYNB Yearly Profit, Operating, Gross MarginsKYNB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • KYNB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • KYNB has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, KYNB has more shares outstanding
  • Compared to 1 year ago, KYNB has a worse debt to assets ratio.
KYNB Yearly Shares OutstandingKYNB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
KYNB Yearly Total Debt VS Total AssetsKYNB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -19.21, we must say that KYNB is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -19.21, KYNB is not doing good in the industry: 82.69% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.21
ROIC/WACCN/A
WACC14.55%
KYNB Yearly LT Debt VS Equity VS FCFKYNB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 3.71 indicates that KYNB has no problem at all paying its short term obligations.
  • KYNB has a Current ratio (3.71) which is in line with its industry peers.
  • KYNB has a Quick Ratio of 3.60. This indicates that KYNB is financially healthy and has no problem in meeting its short term obligations.
  • KYNB has a Quick ratio of 3.60. This is comparable to the rest of the industry: KYNB outperforms 45.58% of its industry peers.
Industry RankSector Rank
Current Ratio 3.71
Quick Ratio 3.6
KYNB Yearly Current Assets VS Current LiabilitesKYNB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 102.02% over the past year.
  • KYNB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.39%.
  • KYNB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -35.07% yearly.
EPS 1Y (TTM)102.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-97.68%

3.2 Future

  • KYNB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.02% yearly.
  • KYNB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -56.79% yearly.
EPS Next Y60.86%
EPS Next 2Y-0.78%
EPS Next 3Y3.05%
EPS Next 5Y9.02%
Revenue Next Year-96.3%
Revenue Next 2Y-81.45%
Revenue Next 3Y-67.47%
Revenue Next 5Y-56.79%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
KYNB Yearly Revenue VS EstimatesKYNB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
KYNB Yearly EPS VS EstimatesKYNB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 11.37, the valuation of KYNB can be described as reasonable.
  • Based on the Price/Earnings ratio, KYNB is valued cheaper than 96.92% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of KYNB to the average of the S&P500 Index (27.13), we can say KYNB is valued rather cheaply.
  • The Forward Price/Earnings Ratio is negative for KYNB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 11.37
Fwd PE N/A
KYNB Price Earnings VS Forward Price EarningsKYNB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYNB Per share dataKYNB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.19
PEG (5Y)N/A
EPS Next 2Y-0.78%
EPS Next 3Y3.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • KYNB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KYNTRA BIO INC

NASDAQ:KYNB (3/2/2026, 8:00:02 PM)

7.05

+0.12 (+1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-16
Inst Owners28.21%
Inst Owner ChangeN/A
Ins Owners1.49%
Ins Owner ChangeN/A
Market Cap28.55M
Revenue(TTM)8.30M
Net Income(TTM)215.65M
Analysts80
Price Target43.86 (522.13%)
Short Float %2.69%
Short Ratio2.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.24%
Min EPS beat(2)20.04%
Max EPS beat(2)20.44%
EPS beat(4)4
Avg EPS beat(4)102.91%
Min EPS beat(4)20.04%
Max EPS beat(4)226.05%
EPS beat(8)7
Avg EPS beat(8)62.43%
EPS beat(12)9
Avg EPS beat(12)43.37%
EPS beat(16)11
Avg EPS beat(16)26.6%
Revenue beat(2)0
Avg Revenue beat(2)-42.72%
Min Revenue beat(2)-49.76%
Max Revenue beat(2)-35.68%
Revenue beat(4)1
Avg Revenue beat(4)-23.81%
Min Revenue beat(4)-87.66%
Max Revenue beat(4)77.86%
Revenue beat(8)4
Avg Revenue beat(8)-0.43%
Revenue beat(12)8
Avg Revenue beat(12)6.67%
Revenue beat(16)9
Avg Revenue beat(16)3.44%
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 11.37
Fwd PE N/A
P/S 3.44
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.62
EY8.79%
EPS(NY)-12.19
Fwd EYN/A
FCF(TTM)-4.22
FCFYN/A
OCF(TTM)-4.18
OCFYN/A
SpS2.05
BVpS-4.2
TBVpS-4.2
PEG (NY)0.19
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 157.4%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 2598.87%
GM 345.69%
FCFM N/A
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.39%
Cap/Sales 2.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.71
Quick Ratio 3.6
Altman-Z -19.21
F-Score5
WACC14.55%
ROIC/WACCN/A
Cap/Depr(3y)133.57%
Cap/Depr(5y)124.53%
Cap/Sales(3y)11.27%
Cap/Sales(5y)9.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
EPS Next Y60.86%
EPS Next 2Y-0.78%
EPS Next 3Y3.05%
EPS Next 5Y9.02%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-97.68%
Revenue Next Year-96.3%
Revenue Next 2Y-81.45%
Revenue Next 3Y-67.47%
Revenue Next 5Y-56.79%
EBIT growth 1Y-29.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.53%
EBIT Next 3Y7.86%
EBIT Next 5Y4.1%
FCF growth 1Y95.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y95.16%
OCF growth 3YN/A
OCF growth 5YN/A

KYNTRA BIO INC / KYNB FAQ

What is the fundamental rating for KYNB stock?

ChartMill assigns a fundamental rating of 2 / 10 to KYNB.


What is the valuation status for KYNB stock?

ChartMill assigns a valuation rating of 3 / 10 to KYNTRA BIO INC (KYNB). This can be considered as Overvalued.


How profitable is KYNTRA BIO INC (KYNB) stock?

KYNTRA BIO INC (KYNB) has a profitability rating of 3 / 10.


How financially healthy is KYNTRA BIO INC?

The financial health rating of KYNTRA BIO INC (KYNB) is 2 / 10.